Blog
8 Articles
Progress and Promise—Research in 2023
What advances were made in 2023 for pancreatic cancer treatments? Where is research headed in the coming year?
NAPOLI-3 Trial Meets Primary Endpoint in Metastatic Disease
Dr. Tanios Bekaii-Saab explains the early positive results from the NAPOLI-3 clinical trial, testing the NALIRIFOX combination.
A Changing Treatment Plan
Shawnee Daniels-Sykes and her doctors have been changing her treatment plan to match her stage IV pancreatic cancer.
Drug Combination to Combat Pancreatic and other Gastrointestinal Cancers
Researchers are testing a drug combination of TAS-102, an approved drug for colorectal cancer, and nanoliposomal irinotecan, on gastrointestinal cancers.
Targeting Cancer-Associated Wasting With Experimental Immunotherapy
Wasting, or cachexia, is the focus of a clinical trial testing a cachexia immunotherapy treatment combined with standard pancreatic cancer treatment.
Comparing a Standard Chemotherapy With and Without a PARP Inhibitor
A clinical trial compares standard chemotherapy with and without the addition of a PARP inihibitor, for patients whose pancreatic cancer is spreading again.
Using a Vitamin to Make Low-Dose Chemotherapy More Effective
A clinical trial compares the effectiveness of low-dose continuous chemotherapy with and without high doses of vitamin C.
Drug Onivyde Gives New Hope to Patients with Advanced Pancreatic Cancer
Onivyde (injectable irinotecan), combined with fluorouracil and leucovorin, has been approved as a second-line treatment for advanced pancreatic cancer.